XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
SIGNIFICANT AGREEMENTS AND CONTRACTS (Details) - Subaward Agreement - CD201 product candidate - USD ($)
$ in Thousands
3 Months Ended
Mar. 30, 2017
Mar. 31, 2018
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Qualifying development expenses to be reimbursed by CARB-X upon acceptance of new initial drug application $ 3,900  
Qualifying development expenses to be reimbursed through a Phase 1 clinical trial of CD201 $ 3,000  
Reduction in research and development expense   $ 3
Billed accounts receivable   100
Unbilled accounts receivable   $ 200
Agreement termination, written notice period 30 days